AlloVir (Nasdaq:ALVR) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ALVR Aperçu des actions

Allovir, Inc. est une société de thérapie cellulaire au stade clinique qui se consacre à la recherche et au développement de thérapies allogéniques à base de cellules T multi-virus spécifiques (VST) pour prévenir et traiter les maladies virales dévastatrices.

A propos de l'entreprise

ALVR analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Les actionnaires ont été dilués au cours de l'année écoulée

N'a pas de capitalisation boursière significative ( $85M )

AlloVir, Inc. Concurrents

Chimerix

NasdaqGM:CMRX

US$84.3m

Instil Bio

NasdaqCM:TIL

US$81.6m

Ovid Therapeutics

NasdaqGS:OVID

US$85.2m

Aligos Therapeutics

NasdaqCM:ALGS

US$81.1m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour AlloVir
Historique des cours de bourse
Prix actuel de l'action	US$0.78
Plus haut sur 52 semaines	US$3.32
Plus bas sur 52 semaines	US$0.58
Bêta	0.77
1Variation sur 1 mois	5.17%
Variation sur 3 mois	3.23%
Variation sur 1 an	-75.80%
3Variation sur 3 ans	-96.14%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-96.93%

Nouvelles et mises à jour récentes

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

Rendement pour les actionnaires

	ALVR	US Biotechs	US Marché
7D	3.9%	0.1%	0.06%
1Y	-75.8%	13.8%	22.6%

Rendement vs Industrie: ALVR a sous-performé le secteur US Biotechs qui a rapporté 14.9 % au cours de l'année écoulée.

Rendement vs marché: ALVR a sous-performé le marché US qui a rapporté 25.4 % au cours de l'année écoulée.

Volatilité des prix

Is ALVR's price volatile compared to industry and market?
ALVR volatility
ALVR Average Weekly Movement	7.0%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: ALVR n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ALVR a diminué de 13% à 7% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2013	8	Diana Brainard	www.allovir.com

Allovir, Inc. est une société de thérapie cellulaire au stade clinique qui se consacre à la recherche et au développement de thérapies allogéniques à base de cellules T spécifiques à plusieurs virus (VST) pour prévenir et traiter les maladies virales dévastatrices. Le produit phare de l'entreprise est le posoleucel, une thérapie allogénique à base de cellules T spécifiques, pour traiter le virus BK, le cytomégalovirus, l'adénovirus, le virus d'Epstein-Barr, l'herpèsvirus humain 6 et le virus JC. Ses produits candidats en développement préclinique et clinique comprennent ALVR106 pour le virus respiratoire syncytial, la grippe, le virus parainfluenza et le métapneumovirus humain ; ALVR109 pour traiter le SARS-CoV-2 et le COVID-19 ; ALVR107 pour traiter l'hépatite B ; et ALVR108.

AlloVir, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de AlloVir se comparent-ils à sa capitalisation boursière ?
ALVR statistiques fondamentales
Capitalisation boursière	US$88.39m
Bénéfices(TTM)	-US$140.34m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-0.6x

Ratio P/E

Le site ALVR est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ALVR compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$140.34m
Les revenus	-US$140.34m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.23
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de ALVR?

Voir les performances historiques et les comparaisons

ALVR Aperçu des actions

Récompenses

Analyse des risques

AlloVir, Inc. Concurrents

NasdaqGM:CMRX

US$84.3m

NasdaqCM:TIL

US$81.6m

NasdaqGS:OVID

US$85.2m

NasdaqCM:ALGS

US$81.1m

Historique des prix et performances

Nouvelles et mises à jour récentes

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

Recent updates

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors